Help Ensure the Safe Use of Secondary Hyperparathyroid Meds

February 2018

The new med etelcalcetide (Parsabiv, PAR-sah-biv) will raise questions about treating hyperparathyroidism in dialysis patients.

Hyperphosphatemia and low vitamin D in renal patients leads to hypocalcemia...which stimulates parathyroid hormone (PTH) release.

This is why the first steps in treating patients with elevated PTH are to control high phosphate and treat vitamin D deficiency.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Med Safety Limit the Use of Injectable Promethazine in Your Hospital
Kidney Disease Help Ensure the Safe Use of Secondary Hyperparathyroid Meds
Anesthesia Be Ready to Expedite Treatment for Malignant Hyperthermia
Critical Care Use Best Practices for Your Targeted Temperature Management Protocols
Interactions Contact Your Lab if Patients Report High Biotin Use
New Drugs Stay Alert for New GLP-1 Agonists and Flozins During Transitions of Care
New Drugs Help Avoid Errors With the New HIV Drug, Juluca
Monitoring Help Answer Questions About Using Continuous Glucose Monitors in the Hospital
Cardiology Help Optimize Medication Management for Stable Coronary Artery Disease
Travel Medicine Be Prepared to Treat Patients With Altitude Illness
New Drugs Stay Alert for New GLP-1 Agonists and Flozins During Transitions of Care
New Drugs Help Avoid Errors With the New HIV Drug, Juluca